EGFR and non-small cell lung carcinoma: Recently, a prospective phase 2 clinical trial, which enrolled 46 patients assessed the efficacy and safety of lower starting doses of afatinib followed by dose modification, according to its toxicity in patients with EGFR mutation-positive NSCLC.